Phase 3 Study Shows Viability of 177Lu-PSMA-617 for Taxane-Naïve Metastatic Castration-Resistant Prostate Cancer
Diagnostic Imaging
SEPTEMBER 19, 2024
The use of 177Lu-PSMA-617 was associated with a significantly longer radiographic progression-free survival and a 12 percent lower rate of grade 3 or higher adverse events in comparison to a change of ARPI therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Let's personalize your content